SCHEMBL16058690

SCHEMBL16058690

CCc1ccc(-c2ccn(C(=O)O)c(=O)c2C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.40
▸ S1PR5 Q9H228 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ EGFR P00533 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ TDP2 O95551 3/20 0.37
▸ MAPT P10636 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ SLC22A12 Q96S37 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ ALPL P05186 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ RXRA P19793 2/20 0.34
▸ RXRB P28702 2/20 0.34
▸ RXRG P48443 1/20 0.34
▸ FFAR4 Q5NUL3 2/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ EDNRB P24530 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057309 0.89 MCL1 (0.40) S1PR1S1PR5ALDH1A1RAB9ASMN1; SMN2
SCHEMBL16056895 0.86 RARB (0.48) ALDH1A1MAPT
SCHEMBL16056806 0.86 LMNA (0.41) ALDH1A1RAB9ASMN1; SMN2KDM4ECA12
SCHEMBL14975270 0.83 KDM4E (0.39) ALDH1A1SMN1; SMN2MAPTCYP1A2KDM4E
SCHEMBL16056988 0.82 RARB (0.40) S1PR1S1PR5ALDH1A1
SCHEMBL16056362 0.82 TPMT (0.32) —
SCHEMBL16057334 0.80 L3MBTL1 (0.42) RAB9AMAPTKDM4EMAPK1
SCHEMBL16057503 0.79 MCL1 (0.42) CA12CA9EDNRBEDNRA
SCHEMBL16057154 0.78 RAB9A (0.42) ALDH1A1RAB9ASMN1; SMN2MAPTCA12
SCHEMBL14977095 0.76 GPR35 (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 S1PR1 1899/4885S1PR5 1406/4885ALDH1A1 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback